Exposure-QT analysis for sonidegib (LDE225), an oral inhibitor of the hedgehog signaling pathway, for measures of the QT prolongation potential in healthy subjects and in patients with advanced solid tumors
Crossref DOI link: https://doi.org/10.1007/s00228-016-2128-8
Published Online: 2016-09-23
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Quinlan, Michelle
Zhou, Jocelyn
Hurh, Eunju
Sellami, Dalila
Funding for this research was provided by:
Novartis Pharmaceuticals Corporation
License valid from 2016-09-23